Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study
Open Access
- 27 February 2024
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 22, 100361
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NR-52284)
- Department of Atomic Energy, Government of India (RTI 4006)
- National Centre for Biological Sciences
- Indian Institute of Science Education and Research Pune
- National Institute of Allergy and Infectious Diseases
This publication has 37 references indexed in Scilit:
- Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trialThe Lancet Infectious Diseases, 2022
- Humoral and cellular immune memory to four COVID-19 vaccinesCell, 2022
- Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workersEBioMedicine, 2022
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variantCell, 2022
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialThe Lancet, 2021
- Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infectionTravel Medicine and Infectious Disease, 2021
- Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) studyVaccine, 2021
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialThe Lancet Infectious Diseases, 2021
- Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral ResponseCell Host & Microbe, 2020